Pfizer Jab May Be Granted 'Full Approval' By FDA As Early As September
The Food and Drug Administration (FDA) may grant full approval for Pfizer’s Covid-19 vaccination as early as September or October, according to the Wall Street Journal, citing FDA advisers and former officials familiar with the process.
The rush for full approval – as opposed to the current emergency use authorization – comes as many schools, hospitals and employers have used full approval as a benchmark for moving forward with mandatory vaccinations.
“We’d like to see it approved as fast as humanly possible, so we can really go back to just the more normal experience,” said Jim Malatras, chancellor of the State University of New York system, who currently cannot impose a vaccine mandate for some 400,000 students served under the system. At present, the school requires either vaccines or weekly testing.
Per Wall Street Journal:
"Three vaccines—from Pfizer Inc. and partner BioNTech SE, Moderna Inc., and Johnson & Johnson —are authorized for emergency use in the U.S. Pfizer and Moderna have filed initial paperwork for full approval. However, only Pfizer has submitted all the necessary information to the FDA, according to the companies, and analysts expect it will be the first to get the green light. Moderna says it is still completing rolling data submissions, and Johnson & Johnson says it plans to file for full approval later this year."
Our latest stories...